{"filing":{"accession_number":"0001437749-26-024746","cik":"0001710340","ticker":"ETON","company_name":"Eton Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"eton20260723_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926024746/eton20260723_8k.htm"},"events":[{"id":21358,"run_id":19264,"accession_number":"0001437749-26-024746","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Eton Pharmaceuticals announced submission of a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI's indication to younger pediatric patients (under age five) with adrenal insufficiency. This is a material regulatory milestone for an existing commercial product—the company is pursuing label expansion to access a larger market segment (\"the largest need for an FDA-approved oral liquid hydrocortisone remains with children under age five\"). While this is clearly operational/strategic in nature and material to investors assessing the company's growth prospects, it does not fit neatly into the specific event categories (not an earnings release, M\u0026A, impairment, litigation, etc.), making operational_other the most appropriate classification.","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":20984,"accession_number":"0001437749-26-024746","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Eton Pharmaceuticals announced submission of a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI's indication to younger pediatric patients (under age five) with adrenal insufficiency. This is a material regulatory milestone for an existing commercial product—the company is pursuing label expansion to access a larger market segment (\"the largest need for an FDA-approved oral liquid hydrocortisone remains with children under age five\"). While this is clearly operational/strategic in nature and material to investors assessing the company's growth prospects, it does not fit neatly into the specific event categories (not an earnings release, M\u0026A, impairment, litigation, etc.), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:01:42.360215+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20984,"accession_number":"0001437749-26-024746","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Eton Pharmaceuticals announced submission of a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI's indication to younger pediatric patients (under age five) with adrenal insufficiency. This is a material regulatory milestone for an existing commercial product—the company is pursuing label expansion to access a larger market segment (\"the largest need for an FDA-approved oral liquid hydrocortisone remains with children under age five\"). While this is clearly operational/strategic in nature and material to investors assessing the company's growth prospects, it does not fit neatly into the specific event categories (not an earnings release, M\u0026A, impairment, litigation, etc.), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:01:42.360215+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-07-29"}]}